Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00562120 · ClinicalTrials.gov registry record · Phase 2
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00562120 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 21 participants.
The verdict
NCT00562120, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhinometry will be used to measure the congestion.
Interventions
- DRUG Placebo
- DRUG PF-03654746
- DRUG Allegra
- DRUG Allegra-D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00562120
The ClinicalTrials.gov registry entry for NCT00562120 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00562120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00562120 about?
NCT00562120 is a clinical study titled "A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge". An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhinometry will be used to measure the congestion.
What is the current status of trial NCT00562120?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2007-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00562120?
The interventions under investigation include: Placebo (DRUG), PF-03654746 (DRUG), Allegra (DRUG), Allegra-D (DRUG).
Who is sponsoring clinical trial NCT00562120?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.